The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSSA.L Regulatory News (SSA)

  • There is currently no data for SSA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sistema PJSFC: Sistema completes merger of OBL Pharm and Binnopharm

14 Oct 2019 07:45

Sistema PJSFC (SSA) Sistema PJSFC: Sistema completes merger of OBL Pharm and Binnopharm 14-Oct-2019 / 09:45 MSK Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


Sistema completes merger of OBL Pharm and Binnopharm 

Moscow, 14 October 2019.  - Sistema PJSFC ("Sistema") (LSE: SSA, MOEX: AFKS), a publicly traded diversified Russian holding company, announces the completion of the merger of pharmaceutical assets JSC Pharmaceutical Enterprise Obolenskoe ("OBL Pharm") and JSC Binnopharm ("Binnopharm"). The merged company will operate under the brand Alium.

As a result of Sistema's participation in an additional issue of OBL Pharm shares, Sistema's effective stake in the company increased from 12.8% to 26.3%. VTB Bank's effective stake in OBL Pharm now stands at 38.5%, while the total stake owned by the consortium of investors including the Russian Direct Investment Fund ("RDIF"), the Russia-China Investment Fund (RCIF, which was created by RDIF and China Investment Corporation) and leading Middle Eastern funds is 23.0%. Sistema paid for its additional shares of OBL Pharm using the 88.7% of Binnopharm shares that it owned.[1]

The merger of OBL Pharm and Binnopharm created pharmaceuticals holding Alium, one of Russia's largest pharma companies in the commercial segment. Alium's total production area exceeds 70,000 sq m and includes four high-tech facilities in Moscow and the Moscow region. The company's diversified product portfolio comprises approximately 200 drugs used across therapeutic areas including respiratory, nervous and gastrointestinal systems, cardiology, infectious diseases and colds as well as pain relief.

***

Sistema PJSFC is a publicly-traded diversified Russian holding company serving over 150 million customers in the sectors of telecommunications, high technology, financial services, retail, paper and packaging, agriculture, real estate, tourism and medical services. The company was founded in 1993. Revenue in 2018 was RUB 777.4 bn; total assets equalled RUB 1.5 trn as of 31 December 2018. Sistema's global depositary receipts are listed under the "SSA" ticker on the London Stock Exchange. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange. Website: www.sistema.com

 

***

For further information, please visit www.sistema.com or contact:

 

 

 

Investor Relations Nikolai Minashin Tel: +7 (495) 730 66 00 n.minashin@sistema.ru

Public Relations Sergey Kopytov Tel.: +7 (495) 228 15 32 kopytov@sistema.ru

   

 

 


[1] As part of the process of merging OBL Pharm and Binnopharm, Sistema increased its stake in Binnopharm to 88.7% by acquiring 14.7% of the company from minority shareholders.


ISIN:US48122U2042
Category Code:MSCM
TIDM:SSA
LEI Code:213800JSZ2UUK4QQK694
Sequence No.:23264
EQS News ID:889435
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
9th Mar 20234:00 pmEQSSistema PJSFC: Sistema Group completes acquisition of hotel business from Wenaas Hotel Russia
5th Mar 20235:30 pmEQSSistema PJSFC: Termination of transaction to purchase a 47.7% stake in Melon Fashion Group
1st Feb 20239:00 amEQSSistema PJSFC: Sistema Group to double its hospitality business
29th Dec 20224:50 pmEQSSistema PJSFC: Director/PDMR Transaction
15th Dec 20227:00 amEQSSistema PJSFC: Sistema announces financial results for the third quarter 2022
19th Oct 20224:10 amEQSSistema PJSFC: Sistema acquires stake in Melon Fashion Group
29th Aug 20228:00 amEQSSistema PJSFC: Sistema announces financial results for the second quarter 2022
16th Aug 20225:55 pmEQSSistema PJSFC: Ad Hoc Notice
15th Aug 20225:55 pmEQSSistema PJSFC: Sistema announces results of Annual General Meeting of Shareholders and Board of Directors meeting
11th Jul 20225:55 pmEQSSistema PJSFC: Sistema announces results of Extraordinary General Meeting of Shareholders and Board of Directors meeting
28th Jun 20222:00 pmEQSSistema PJSFC: Report on Payments to Governments for 2021
16th Jun 20226:20 pmEQSSistema PJSFC: Change in the list of nominees for the new Board of Directors of Sistema
10th Jun 20223:30 pmEQSSistema PJSFC: Sistema announces nominees to Board of Directors
9th Jun 20228:00 amEQSSistema PJSFC: Sistema announces financial results for the first quarter 2022
20th May 20223:30 pmEQSSistema PJSFC: Sistema announces EGM results
19th May 20225:00 pmEQSSistema PJSFC: Sistema received permission to retain the depository receipts program
5th May 20225:50 pmEQSSistema PJSFC: Sistema announces EGM date
5th May 202211:10 amEQSSistema PJSFC: Ad-Hoc Notice
4th May 20226:40 pmEQSSistema PJSFC: Sistema increases effective stake in Etalon Group to 48.8%
29th Apr 20228:30 amEQSSistema PJSFC: Sistema Annual Report 2021
27th Apr 20225:50 pmEQSSistema PJSFC: Ad-Hoc Notice
16th Apr 20229:00 amEQSSistema PJSFC: CORRECTION: Director/PDMR Transaction
15th Apr 20225:55 pmEQSSistema PJSFC: Director/PDMR Transaction
15th Apr 20221:00 pmEQSSistema PJSFC: Sistema announces decisions of the Board of Directors
13th Apr 20223:45 pmEQSSistema PJSFC: Ad-Hoc Notice
13th Apr 20223:45 pmEQSSistema PJSFC: Director/PDMR Transaction
7th Apr 20225:30 pmEQSSistema PJSFC: Ad-Hoc Notice
7th Apr 20227:56 amEQSSistema PJSFC: Sistema announces financial results for the fourth quarter and FY 2021
5th Apr 20225:00 pmEQSSistema PJSFC: Sistema announces AGM date
4th Apr 202210:00 amEQSSistema PJSFC: Fitch Ratings action on Russian entities
24th Mar 20222:26 pmEQSSistema PJSFC: MTS CEO Increases Stake in Company
14th Mar 20228:30 amEQSSistema PJSFC: Rating action by Fitch
4th Mar 20224:45 pmEQSSistema PJSFC: Fitch takes rating action on Sistema following sovereign downgrade
1st Mar 20224:43 pmRNSSecond Price Monitoring Extn
1st Mar 20224:35 pmRNSPrice Monitoring Extension
25th Feb 20224:42 pmRNSSecond Price Monitoring Extn
25th Feb 20224:36 pmRNSPrice Monitoring Extension
24th Feb 20224:42 pmRNSSecond Price Monitoring Extn
24th Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20224:45 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
24th Jan 20224:00 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
17th Jan 20224:00 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
30th Dec 20214:00 pmEQSSistema PJSFC:  Director/PDMR Transaction
29th Dec 20214:00 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
29th Dec 20211:00 pmEQSSistema PJSFC: Sistema completes sale of minority stake in Segezha Group
27th Dec 20214:05 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
20th Dec 20214:05 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
14th Dec 20216:50 amEQSSistema PJSFC: Sistema increases effective stake in Binnopharm Group to 75.3%
13th Dec 20214:05 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme
6th Dec 20214:00 pmEQSSistema PJSFC: Sistema reports acquisition of shares under buyback programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.